Haleos Labs Q1 FY27: Sales ₹72.94cr, PAT down YoY

Key takeaway from the June 2026 quarter

Haleos Labs’ June 2026 quarter (Q1 FY27) showed broad pressure across revenue and profitability metrics, as consolidated net sales fell to ₹72.94 crore. The company’s consolidated net profit was reported at ₹2.65 crore, down 36.30% year-on-year (YoY), alongside a sharp drop in profit margins. The quarter was described as the weakest in recent quarters, with sales also declining sequentially versus the March 2026 quarter. Operating profitability weakened, and the tax outgo rose further, adding to the pressure on bottom-line performance. Haleos Labs’ board approved the unaudited standalone and consolidated financial results in its 98th meeting held on August 5, 2026. The company’s numbers were reported on August 6, 2026, during the quarterly results season. The data in this report reflects figures presented in the provided results summary.

Revenue slips to a recent low

For Q1 FY27, consolidated net sales were ₹72.94 crore, down 11.59% YoY from ₹82.50 crore in Q1 FY26. The same dataset also shows a sequential decline of 2.93% from ₹75.14 crore in Q4 FY26. The narrative accompanying the data called this the company’s weakest quarterly performance in “recent memory,” highlighting the extent of the slowdown. A separate summary also referenced consolidated revenue of about ₹72 crore for the quarter ended June 30, 2026, consistent with the ₹72.94 crore figure. On a standalone basis, revenue from operations was cited at ₹67.83 crore, up 7% quarter-on-quarter (QoQ) but down 14% YoY from ₹79.04 crore. Other income fell to ₹45.61 lakh from ₹100.94 lakh in the year-ago period, reducing the cushion that non-operating income can provide when core performance softens.

Margins compress as operating performance weakens

Profitability compressed notably in Q1 FY27. The operating margin (excluding other income) was stated at 12.49%, down 167 basis points YoY from 14.19%. Operating profit before depreciation, interest, tax, and other income (PBDIT excluding OI) stood at ₹9.11 crore, aligning with the lower operating margin. The profit after tax (PAT) margin was reported at 2.52%, down 279 basis points YoY from 5.31% in Q1 FY26, signalling a sharp contraction in net profitability. The results note also flagged “earnings quality concerns,” stating that profit before tax (excluding other income) fell 50.50% in Q1 FY27 to ₹2.98 crore. These data points collectively indicate that the pressure was not limited to one line item but spread across revenue, operating profitability, and reported earnings.

Tax rate rises, further eroding net profit

The results summary highlighted that an abnormally high tax rate of 46.51% in Q1 FY27, compared with 37.61% in Q1 FY26, further reduced net profitability. In the same context, the summary stated standalone PAT of ₹1.84 crore and consolidated PAT of ₹2.65 crore for the quarter. Another table of key financial metrics also presented net profit of ₹1.8403 crore at the consolidated level (₹184.03 lakh), reflecting that different summaries in the provided dataset use different profit line definitions and bases. What remains consistent across the narrative is that the bottom line weakened materially YoY while the tax burden increased.

Quarter-by-quarter trend shows volatility

The quarterly comparison table included in the dataset shows significant volatility across the last four quarters, with sales swinging and profitability moving sharply.

The pattern shows that while December 2025 and September 2025 had stronger profitability, March 2026 saw a sharp drop in net profit, followed by a partial recovery in June 2026 but with materially lower margins than the stronger quarters.

Standalone vs consolidated snapshot

The filing-style data provided also shared a consolidated and standalone snapshot in ₹ lakh, which converts to ₹ crore for easier comparison.

The company also disclosed that its subsidiary, Mahi Drugs Private Limited, reported total revenue of ₹10.25 crore and a net loss after tax of ₹20.16 crore for the quarter, which management stated was not material to the group.

Market reaction and pricing snapshots

On the day referenced in the results summary, shares traded around ₹1,427.7 on the NSE and were down 7.27%. The dataset also included other price snapshots such as a CMP of ₹1,564 and a “current price” of ₹1,618.60, indicating that the quoted market price varied across different points in time within the compiled text. What is clear from the results-day reference is that the immediate reaction described was negative.

Why the results matter for investors

The Q1 FY27 numbers highlight a combination of weaker sales, margin compression, and a higher effective tax rate. Revenue from operations dropped on a consolidated basis, and operating margin (excluding other income) declined YoY, showing pressure in core operations. The fall in profit before tax (excluding other income) to ₹2.98 crore was explicitly cited as a sign of stress in underlying profitability. At the same time, the drop in other income and the higher tax rate removed buffers that sometimes soften the impact of a weak operating quarter. The disclosures around subsidiary performance also matter because investors often track whether losses at group entities are becoming financially meaningful, even when management classifies them as not material.

Conclusion

Haleos Labs’ Q1 FY27 performance was marked by consolidated net sales of ₹72.94 crore and consolidated PAT reported at ₹2.65 crore, with operating and PAT margins declining YoY. The board approved the unaudited results on August 5, 2026, and the figures were reported on August 6, 2026. Investors tracking the company will likely focus on whether sales recover from the June 2026 low and whether operating margins and the effective tax rate normalise in subsequent quarters, based on future exchange filings and management updates.